109 related articles for article (PubMed ID: 30146854)
1. RATIONAL USE OF SERUM TUMOUR MARKERS IN DIAGNOSTICS AND TREATMENT OF SOLID TUMOURS.
Plavetić ND; Gnjidić M; Kulić A; Ivić M; Kukec I; Vidović M
Lijec Vjesn; 2016; 138(3-4):85-92. PubMed ID: 30146854
[TBL] [Abstract][Full Text] [Related]
2. Correlation of tumour markers in ascitic fluid and serum: are measurements of ascitic tumour markers a futile attempt?
Tuzun Y; Celik Y; Bayan K; Yilmaz S; Dursun M; Canoruc F
J Int Med Res; 2009; 37(1):79-86. PubMed ID: 19215676
[TBL] [Abstract][Full Text] [Related]
3. [Clinical usefulness of circulating tumor markers].
Ohkura H
Gan To Kagaku Ryoho; 2004 Jul; 31(7):1131-4. PubMed ID: 15272600
[TBL] [Abstract][Full Text] [Related]
4. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
[TBL] [Abstract][Full Text] [Related]
5. Does the assessment of serum markers in patients with lung cancer aid in the clinical decision making process?
Ebert W; Muley T; Drings P
Anticancer Res; 1996; 16(4B):2161-8. PubMed ID: 8694537
[TBL] [Abstract][Full Text] [Related]
6. Clinical application of tumour markers: a review.
Amayo AA; Kuria JG
East Afr Med J; 2009 Dec; 86(12 Suppl):S76-83. PubMed ID: 21591514
[TBL] [Abstract][Full Text] [Related]
7. Increased plasma concentrations of tumour markers in the absence of neoplasia.
Trapé J; Filella X; Alsina-Donadeu M; Juan-Pereira L; Bosch-Ferrer Á; Rigo-Bonnin R;
Clin Chem Lab Med; 2011 Oct; 49(10):1605-20. PubMed ID: 21892908
[TBL] [Abstract][Full Text] [Related]
8. [Clinical relevance of tumor markers].
Lamerz R
Wien Klin Wochenschr; 1989 Jul; 101(14):464-72. PubMed ID: 2672606
[TBL] [Abstract][Full Text] [Related]
9. Serum tumour markers in patients with chronic kidney disease.
Xiaofang Y; Yue Z; Xialian X; Zhibin Y
Scand J Clin Lab Invest; 2007; 67(6):661-7. PubMed ID: 17852811
[TBL] [Abstract][Full Text] [Related]
10. Cancers Screening in an Asymptomatic Population by Using Multiple Tumour Markers.
Wang HY; Hsieh CH; Wen CN; Wen YH; Chen CH; Lu JJ
PLoS One; 2016; 11(6):e0158285. PubMed ID: 27355357
[TBL] [Abstract][Full Text] [Related]
11. Mucins CA 125, CA 19.9, CA 15.3 and TAG-72.3 as tumor markers in patients with lung cancer: comparison with CYFRA 21-1, CEA, SCC and NSE.
Molina R; Auge JM; Escudero JM; Marrades R; Viñolas N; Carcereny E; Ramirez J; Filella X
Tumour Biol; 2008; 29(6):371-80. PubMed ID: 19060513
[TBL] [Abstract][Full Text] [Related]
12. Value of tumour and inflammatory markers in lung cancer.
Oremek GM; Sauer-Eppel H; Bruzdziak TH
Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794
[TBL] [Abstract][Full Text] [Related]
13. Are laboratory investigations recommended in current medical practice guidelines supported by available evidence?
Watine J
Clin Chem Lab Med; 2002 Mar; 40(3):252-5. PubMed ID: 12005215
[TBL] [Abstract][Full Text] [Related]
14. Glycoproteins in the Sera of Oncological Patients.
Hernychová L; Uhrík L; Nenutil R; Novotný MV
Klin Onkol; 2019; 32(Supplementum 3):39-45. PubMed ID: 31627705
[TBL] [Abstract][Full Text] [Related]
15. Serum tumour markers in testicular and extragonadal germ cell malignancies.
Klepp O
Scand J Clin Lab Invest Suppl; 1991; 206():28-41. PubMed ID: 1947758
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic value of chest radiography, computed tomography and tumour markers in the differentiation of malignant from benign solitary pulmonary lesions.
Seemann MD; Seemann O; Dienemann H; Schalhorn A; Prime G; Fink U
Eur J Med Res; 1999 Aug; 4(8):313-27. PubMed ID: 10471543
[TBL] [Abstract][Full Text] [Related]
17. Alpha-fetoprotein and beta-human chorionic gonadotropin: their clinical significance as tumour markers.
Gregory JJ; Finlay JL
Drugs; 1999 Apr; 57(4):463-7. PubMed ID: 10235686
[TBL] [Abstract][Full Text] [Related]
18. An audit of tumour marker utilization in Greece.
Ntaios G; Hatzitolios A; Chatzinikolaou A; Karalazou P; Savopoulos C; Karamouzis M; Pidonia I
Eur J Intern Med; 2009 May; 20(3):e66-9. PubMed ID: 19393482
[TBL] [Abstract][Full Text] [Related]
19. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases.
Nicolini A; Tartarelli G; Carpi A; Metelli MR; Ferrari P; Anselmi L; Conte M; Berti P; Miccoli P
BMC Cancer; 2006 Nov; 6():269. PubMed ID: 17116247
[TBL] [Abstract][Full Text] [Related]
20. Serum tumour markers in clinical practice. Some general aspects.
Kvinnsland S
Scand J Clin Lab Invest Suppl; 1991; 206():6-11. PubMed ID: 1947761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
